|
Mechanism5-HT receptor modulators [+2] |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Double-blind, Randomized, Dose-response Study of RE02 in Healthy Subjects
The goal of this clinical trial is to compare corresponding inter- and intraindividual pharmacokinetic and pharmacodynamic profiles including assessments of safety & tolerability of three different doses against a placebo control.
Single-blind, Randomized, Two-arm, Dose-response Study of DMT and Harmine in Healthy Subjects
The goal of this clinical trial is to compare corresponding inter- and intraindividual pharmacokinetic and pharmacodynamic profiles including assessments of safety & tolerability.
100 Clinical Results associated with Reconnect Labs
0 Patents (Medical) associated with Reconnect Labs
100 Deals associated with Reconnect Labs
100 Translational Medicine associated with Reconnect Labs